Find a Tender
complete
Published value
Not published
Submission deadline Not published
Lots published4
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS): "TCAT - RTX Project". Published status: complete. Published value: Value not published. 4 published lots. Submission deadline not published. See the official notice for participation instructions.
| Contracting Authority | The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS) | Scope & Categories | Not published | Submission Window | complete No deadline published |
|---|---|---|---|---|---|
| Submission Gateway | Direct notice route | Legal Basis & Regime | Standard procurement | Estimated Value (exc. VAT) | Not published |
Bidder Intelligence · Authority Profile: The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
Market Analytics
Derived from OCDS awards & bid statistics
Published history for The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS). These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Average Price Reduction
Not availableInsufficient comparable data
Competition Density
6.9Bids / Report
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate availablePayment Terms
Check noticePublished terms
Coverage: 579 active published awards; 550 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Price reduction compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Procedure methodNot published | Procurement categoryNot published | |
Statuscomplete | Framework / DPSNot published | CompetitionNot published |
Above thresholdNot published | Legal basisNot published | Tender period startsNot published |
Clarification deadlineNot published | Electronic submissionNot published | Submission languagesNot published |
Published17 Jan 2025, 15:04 GMT | Last source update17 Jan 2025, 15:04 GMT | Recurring procurementNot published |
ClassificationLaboratory reagents | ||
Delivery area | ||
OCIDocds-h6vhtk-04cdd6 | ||
What is being bought
SNBTS are under contract with RTx to manufacture the RTX001 product throughout 2025. RTx have transferred their manufacturing procedure to SNBTS and SNBTS are required to use the reagents/consumables specified by RTx within that process.
What changed
From the official release history
- Official notice release published
17 Jan 2025, 15:04 GMT - Status changed to complete
7 Jan 2025, 13:46 GMT - Official notice release published
7 Jan 2025, 13:46 GMT - Buyer information updated
7 Jan 2025, 13:46 GMT
Lots and requirements (4)
Published by the contracting authority
- Lot 1 · #1CytokinescancelledPublished valueNot publishedSNBTS are under contract with RTx to manufacture the RTX001 product throughout 2025. RTx have transferred their manufacturing procedure to SNBTS and SNBTS are required to use the reagents/consumables specified by RTx within that process. BioTechne were the chosen supplier of cytokines for use within the trial by RTX, therefore SNBTS are required to procure these reagents from this supplier.Contract periodNot publishedEligibilityNot publishedOptions / renewalNot published
- Lot 2 · #2P3 buffer and nucleofector consumablescancelledPublished valueNot publishedSNBTS are under contract with RTx to manufacture the RTX001 product throughout 2025. RTx have transferred their manufacturing procedure to SNBTS and SNBTS are required to use the reagents/consumables specified by RTx within that process. Lonza were the chosen supplier for P3 buffer and nucleofector consumables for use within the trial by RTX, therefore SNBTS are required to procure these items from this supplier.Contract periodNot publishedEligibilityNot publishedOptions / renewalNot published
- Lot 3 · #3Prodigy cell processorcancelledPublished valueNot publishedSNBTS are under contract with RTx to manufacture the RTX001 product throughout 2025. RTx have transferred their manufacturing procedure to SNBTS and SNBTS are required to use the reagents/consumables specified by RTx within that process. Miltenyi were the chosen supplier of several goods for use within the trial by RTX, therefore SNBTS are required to procure these reagents from this supplier. The goods are for use with the Prodigy cell processor and subsequent downstream processing. The Prodigy does not accept reagents/consumables which are not compatible with the software, therefore the items from Miltenyi are the only suitable goods for use within the trial.Contract periodNot publishedEligibilityNot publishedOptions / renewalNot published
- Lot 4 · #4Rotea kitscancelledPublished valueNot publishedSNBTS are under contract with RTx to manufacture the RTX001 product throughout 2025. RTx have transferred their manufacturing procedure to SNBTS and SNBTS are required to use the reagents/consumables specified by RTx within that process. Rotea have designed their process to use the Rotea cell processor, which requires specific Rotea kits to be used with it. Life Technologies are the only supplier of Rotea kits.Contract periodNot publishedEligibilityNot publishedOptions / renewalNot published
Timeline
- Procedure published
17 Jan 2025, 15:04 GMT - Award active
Not published · Not published - Award active
Not published · Not published - Award active
Not published · Not published - Award active
Not published · Not published - Contract active
Signed 18 Dec 2024, 00:00 GMT · £509,000 - Contract active
Signed 18 Dec 2024, 00:00 GMT · £206,000 - Contract active
Signed 18 Dec 2024, 00:00 GMT · £631,000 - Contract active
Signed 18 Dec 2024, 00:00 GMT · £55,300
Commercial outcome and competition
Awards Bio-Techne Not published · Not published · active Lonza Not published · Not published · active Miltenyi Biotec Ltd. Not published · Not published · active Life Technologies Not published · Not published · active |
Contracts Cytokines £509,000 · signed 18 Dec 2024, 00:00 GMT · active P3 buffer and nucleofector consumables £206,000 · signed 18 Dec 2024, 00:00 GMT · active Prodigy cell processor £631,000 · signed 18 Dec 2024, 00:00 GMT · active Rotea kits £55,300 · signed 18 Dec 2024, 00:00 GMT · active |
Bid statistics bids: 1 (lot 1) electronicBids: 0 (lot 1) foreignBidsFromEU: 0 (lot 1) foreignBidsFromNonEU: 0 (lot 1) smeBids: 0 (lot 1) bids: 1 (lot 2) electronicBids: 0 (lot 2) foreignBidsFromEU: 0 (lot 2) foreignBidsFromNonEU: 0 (lot 2) smeBids: 0 (lot 2) bids: 1 (lot 3) electronicBids: 0 (lot 3) foreignBidsFromEU: 0 (lot 3) foreignBidsFromNonEU: 0 (lot 3) smeBids: 0 (lot 3) bids: 1 (lot 4) electronicBids: 0 (lot 4) foreignBidsFromEU: 0 (lot 4) foreignBidsFromNonEU: 0 (lot 4) smeBids: 0 (lot 4) |
Buyer and organisations in this procedure
The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
Contracting authority GB-FTS-115937Documents (0)
Official links; attachments are not copied
No linked documents are published
Related procedures (0)
No related procedures published
Planning and rationale
Planning budgetNot published |
No-engagement rationaleNot published |
Procedure rationaleSNBTS are under contract with RTx to manufacture the RTX001 product throughout 2025. RTx have transferred their manufacturing procedure to SNBTS and SNBTS are required to use the reagents/consumables specified by RTx within that process. |